Automated #deeplearning systems #ArtificialIntelligence identify & predict joint damage in hand radiographs from #RheumatoidArthritis patients ➡️May aid in monitoring joint damage #ACR23 👉🏽https://t.co/IcoZHY6lns https://t.co/mZWg6YIUp3

ABS0433: ⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective ➡️Retrospect, obs using Medicare data ➡️At least 66 yo old w/ new dx of late-onset RA (LORA) 🚩If no contraindications, start DMARDs early in LORA! #ACR23 @RheumNow https://t.co/ChalcgtS2O

Super interesting study re: impact of ORAL SURVEILLANCE on prescribing Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD) I know many have mixed feelings, but I believe in the risk & support this type of shift @RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1

ABS0450 ⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients ➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97) ➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi #ACR23 @RheumNow https://t.co/yydS20hNzM

ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno

Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb https://t.co/n6CL8G01Wo

Finger fold index (FFI) calculated by deep neural network model reliable for metrical analysis and detection of swelling in RA with 91% accuracy. Mean FFI significantly higher in RA vs healthy controls PIP joints @marcblanchard23 Abst#0402 #ACR23 @RheumNow https://t.co/jmPvwzf2m8 https://t.co/DOZoV0xSsd

TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety. “This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann #ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ

More on TLL-018 How? A: Everyone surprised. But maybe dual mech benefits re: pain via IFN Where’s the multinational RCT in RA? A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent. #ACR23 @RheumNow

What if we deliver TNFi to the wrong place? Delivery of ETA to peripheral lymphatics instead of subcut through a wearable device in 10pts showed: 1- is Safe 2-Reduces DAS28 (but more TJC than SJC) To be confirmed in larger and controlled study! @RheumNow #ACR23 ABST0838 https://t.co/IUPpFwjjbj

Taylor et al. Positive phase 2 RCT of Nipocalimab (neonatal Fc receptor blocking monoclonal) in RA. Abstr#0839 #ACR23 @RheumNow https://t.co/UHjti200yh https://t.co/tkSlLMIl7X

Ph2a Nipocalumab: FcRn blocker IV15mg/kg TNF IR RA 32 pts Delta DASCRP -1 vs -0.5 PBO ACR50 20% vs 0 PBO DAS Remission 40% vs 16% Only in ACPA+ pts SAEs 1 infusion related reaction Not extremely convincing alone Currently studied in combination w/ TNFi @RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN

Ross et al. Fascinating study of infusion of etanercept into lymphatics in RA in inadequate responders to s/c etanercept. DAS28(CRP) reduced 5.40±0.16 to 3.55±0.21, PGA of Disease Activity and Pain decreased by 66% and 77%. Abstr#0838 #ACR23 @RheumNow https://t.co/RIMCS3nmy6 https://t.co/U2689atvmj

APIPPRA trial of abatacept to prevent RA in sero+ arthralgia. Picture paints a thousand words - big difference at week 52 (on abatacept) and watch those lines converge Abstr#0835 #ACR23 #ACRbest @RheumNow https://t.co/cwX389TUZN https://t.co/2CQHYlW0nq